PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|July 22, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-03-2016
- Volume 11
- Issue 8
Recipharm Expands Blow-Fill-Seal Capacity at France Facility
Author(s)Pharmaceutical Technology Editors
The company will invest €18 million in its Kaysersberg facility to expand blow-fill-seal capacity.
Advertisement
On July 5, 2016, Recipharm announced that the company will invest €18 million (approximately $19.73) to expand blow-fill-seal (BFS) capacity at its site in Kaysersberg, France. The investment will include the introduction of a BFS high-speed filling and packaging line, Recipharm said in a press announcement. Recihparm’s Kaysersberg site is a sterile facility specializing in BFS technology for sterile liquids.
Recipharm says it will also prepare to add three additional filling lines to the facility in upcoming years, increasing the company’s BFS capacity by 50%. Yves Buelens, general manager of the Kaysersberg site, said the company is experiencing increased demand for BFS services. “We are experiencing increased demand for our blow-fill-seal services from markets including the United States, Turkey, Australia, and Canada, and the new filling line will help us to meet this growing need,” Buelens noted in a press announcement.
Source: Recipharm
Articles in this issue
about 10 years ago
Slower Bio/Pharma Investment Could Hurt CDMOs in 2017about 10 years ago
Supply Chain Partner Scrutiny Moves Beyond GMPsabout 10 years ago
Chiral Advances Demonstrate Promise for API Synthesisabout 10 years ago
NIST Issues mAb Reference Standardabout 10 years ago
EMA Suspends Drugs Due to Flawed Bioequivalence Studiesabout 10 years ago
CordenPharma Expands into Oligonucleotide APIsabout 10 years ago
Shimadzu System Combines HPLC and UHPLC Methodsabout 10 years ago
Catalent to Commercially Supply Palatin FSD Pen Injectorsabout 10 years ago
Zenith Appoints Serialization DirectorAdvertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement